SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement
- PMID: 22311359
SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement
Abstract
1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).
Similar articles
-
Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway.J Virol. 2011 Oct;85(20):10582-97. doi: 10.1128/JVI.00671-11. Epub 2011 Jul 20. J Virol. 2011. PMID: 21775467 Free PMC article.
-
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14. doi: 10.1016/j.bbrc.2014.07.090. Epub 2014 Jul 26. Biochem Biophys Res Commun. 2014. PMID: 25073113 Free PMC article.
-
Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model.J Infect Dis. 2011 Jun 1;203(11):1574-81. doi: 10.1093/infdis/jir084. J Infect Dis. 2011. PMID: 21592986 Free PMC article.
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Nat Rev Microbiol. 2009. PMID: 19198616 Free PMC article. Review.
-
Vaccine design for severe acute respiratory syndrome coronavirus.Viral Immunol. 2005;18(2):327-32. doi: 10.1089/vim.2005.18.327. Viral Immunol. 2005. PMID: 16035944 Review.
Cited by
-
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector.Mol Biol. 2020;54(6):812-826. doi: 10.1134/S0026893320060151. Epub 2020 Sep 4. Mol Biol. 2020. PMID: 32921819 Free PMC article.
-
Molecular Basis of Coronavirus Virulence and Vaccine Development.Adv Virus Res. 2016;96:245-286. doi: 10.1016/bs.aivir.2016.08.003. Epub 2016 Aug 30. Adv Virus Res. 2016. PMID: 27712626 Free PMC article. Review.
-
Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle.Vaccines (Basel). 2021 Nov 17;9(11):1347. doi: 10.3390/vaccines9111347. Vaccines (Basel). 2021. PMID: 34835278 Free PMC article.
-
Membrane Protein of Human Coronavirus NL63 Is Responsible for Interaction with the Adhesion Receptor.J Virol. 2019 Sep 12;93(19):e00355-19. doi: 10.1128/JVI.00355-19. Print 2019 Oct 1. J Virol. 2019. PMID: 31315999 Free PMC article.
-
A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19.Ann Transl Med. 2020 Dec;8(24):1686. doi: 10.21037/atm-20-5272. Ann Transl Med. 2020. PMID: 33490198 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
